Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.

Journal of hematology & oncology - 14 Feb 2017

Camus Vincent, Miloudi Hadjer, Taly Antoine, Sola Brigitte, Jardin Fabrice

Abstract excerpt

Many recent publications highlight the large role of the pivotal eukaryotic nuclear export protein exportin-1 (XPO1) in the oncogenesis of several malignancies, and there is emerging evidence that XPO1 inhibition is a key target against cancer. The clinical validation of the pharmacological inhibition of XPO1 was recently achieved with the development of the selective inhibitor of nuclear export compounds,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Exportin 1 Protein
Share to Hematologic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hodgkin Disease

Share to Karyopherins

Share to Lymphoma, Large B-Cell, Diffuse

Share to Molecular Targeted Therapy

Share to Receptors, Cytoplasmic and Nuclear

Source

Open in PubMed Open full text

Identifiers

PMID: 28196522
DOI: 10.1186/s13045-017-0412-4
PMCID: PMC5307790

Genes

XPO1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.PMID 28196522Read ↗

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Semantic proximity Read ↗

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.Semantic proximity Read ↗

Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesisSemantic proximity Read ↗

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.Semantic proximity Read ↗

Targeting XPO1-Dependent Nuclear Export in Cancer.Semantic proximity Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

Protein biomarkers for response to XPO1 inhibition in haematologic malignanciesSemantic proximity Read ↗

NPM1-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment StrategiesSemantic proximity Read ↗

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition.Semantic proximity Read ↗

Targeting nuclear import and export in hematological malignanciesSemantic proximity Read ↗

XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.Semantic proximity Read ↗

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in <i>NPM1</i> -mutated AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.